Alyeska Investment Group
XFOR icon

Alyeska Investment Group’s X4 Pharmaceuticals XFOR Stock Holding History

Alyeska Investment Group’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,000
Closed -$1.4M – 600
2020
Q2 		$1.4M Hold
5,000
– – 0.02% 382
2020
Q1 		$1.5M Hold
5,000
– – 0.03% 274
2019
Q4 		$1.6M Buy
5,000
+3,333
+200% +$1.2M 0.02% 310
2019
Q3 		$636K Hold
1,667
– – 0.01% 348
2019
Q2 		$750K Buy
+1,667
New +$847K 0.01% 382

Other funds holding XFOR

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Alyeska Investment Group's XFOR Position: Q1 2021 in Review

Alyeska Investment Group sold out of X4 Pharmaceuticals (XFOR) in Q1 2021, closing a stake of 2,230 shares — an estimated $430K sold.

Alyeska Investment Group first reported a position in XFOR in Q4 2017 and held it in 6 quarters. The position peaked at $2.01M in Q4 2019. 60 funds tracked by Wall St. Rank hold XFOR as of Q1 2021.

  • Alyeska Investment Group reported no remaining X4 Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 2,230 X4 Pharmaceuticals shares in Q1 2021, an estimated $430K.
  • Alyeska Investment Group first reported a position in X4 Pharmaceuticals in Q4 2017 and held it in 6 quarters.
  • Alyeska Investment Group's X4 Pharmaceuticals position peaked at $2.01M in Q4 2019.
  • 60 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2021.

Based on Alyeska Investment Group's 13F filing for Q1 2021, filed 17 May 2021.